Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Foresite promotes Hyung Chun, Cindy Xiong to partner

Plus: Peter Flynn at the helm at Arialys, and updates from Augustine, CND, Parallel Bio and Zevra

June 27, 2024 1:08 AM UTC

Foresite Capital promoted Hyung Chun and Cindy Xiong to partners. In this role, Chun and Xiong will find new investment opportunities in therapeutics while continuing to oversee existing investments. The firm is leaning in to AI and data science as it invests its new $900 million sixth fund, continuing a trend that has deepened this decade and has led up to one of the firm’s largest deals yet.

Avalon-incubated start-up  Arialys Therapeutics Inc., which is developing therapies for autoimmune-driven psychiatric conditions, named Peter Flynn president and CEO. He succeeds Jay Lichter, managing partner of Avalon, who will become chairman. Flynn co-founded Artiva Biotherapeutics Inc., where he was COO. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article